NASDAQ:LGVN The clinical stage biotechnology company developing cellular therapies for life-threatening conditions, Longeveron Inc. (NASDAQ: LGVN) has been regaining some of the momentum it lost following its 128% surge. Considering that its Alzheimer's treatment showed impressive results in its phase 1 trials, many investors believe LGVN stock could be a...
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is...
lvgn being held back by its top trendline resistance and in a nasty downtrend. I have seen this pattern too many times, 1-2 days of crazy upside, traps longs and then it never comes back to highs.
my price targets are 9.29-6.08-3.25
be careful if long here, and goodluck! like and follow for more 💘
Longeveron stock is up by a multiple of 11 after the FDA gave a Rare Pediatric Disease designation for a heart medication last week.
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy...
It seems like everybody is bullish on this - for obvious reasons short-term - but I feel like there might a move for the imbalances around the $23 and $18 levels.
No idea what it might do at these levels but I do suspect a move down to them in the coming hours/days.
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult...
